Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

Clinical trial NCT07455032 · RECRUITING

Trial details

NCT number: NCT07455032
Sponsor: Fox Chase Cancer Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Squamous Cell Carcinoma of Head and Neck

Start date: 2026-04-08
Primary completion: 2027-11-30
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.